177Lu PSMA 617 + NOX66 (IMAGE)

Society of Nuclear Medicine and Molecular Imaging

177Lu PSMA 617 + NOX66

Caption

Marked reduction in metabolically active disease in response to a combination of 177Lu PSMA 617 + NOX66 therapy in end-stage, high-volume castrate resistant metastatic prostate cancer. The PSA continued to fall for 6 months after completion of therapy, and the patient remains well 20 months after trial enrollment.

Credit

Credit: Emmett L, Crumbaker M, Nguyen A, et al.

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.